Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06533527
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-27
Brief Title:
Holding vs Continuing Incretin-based Therapies Before Upper Endoscopy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Randomized Trial of Holding vs Continuing Incretin-based Therapies Before Upper Endoscopy
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume RGV
Primary Outcomes
Residual gastric volume that precludes adequate endoscopic examination
Residual gastric volume that necessitates premature termination of the endoscopy procedure
Need for endotracheal intubation due to stomach contents
Occurrence of aspiration events requiring extended observationmonitoring unplanned therapeutics andor hospital admission
Secondary Outcomes
Presence of any solid food
Presence of moderate liquid content
Increased RGVResidual Gastric Volume defined as any amount of solid content or 08 mLKg of fluid content measured from the aspirationsuction canister
Differences in primary and secondary outcomes between different medications
Primary Outcomes
Residual gastric volume that precludes adequate endoscopic examination
Residual gastric volume that necessitates premature termination of the endoscopy procedure
Need for endotracheal intubation due to stomach contents
Occurrence of aspiration events requiring extended observationmonitoring unplanned therapeutics andor hospital admission
Secondary Outcomes
Presence of any solid food
Presence of moderate liquid content
Increased RGVResidual Gastric Volume defined as any amount of solid content or 08 mLKg of fluid content measured from the aspirationsuction canister
Differences in primary and secondary outcomes between different medications
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None